MDXH · MDxHealth SA
$0.81
+0.35 (+74.89%)
At close · Aug 14
Market Cap
$41.50M
Shares
51.36M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.81
Open$0.61
Day$0.58–1.13
52W close$0.40–5.00
Avg vol 30d11.4M
Short int1.1M · 2.1% float · 5.0d
Short vol55%
Last earningsMar 31, 2026
DataNov 2021–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−66%
below
Price vs 50-day avg
+69%
above
RSI (14)
80
overbought
MACD trend
Positive
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+91%
trailing
6-month return
−78%
trailing
YTD return
−77%
this year
Relative strength
−91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.07% of float · ▲ +11.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 2-yr range
Squeeze score
81
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
10.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
2026 revenue guidance for our core cancer business, excluding Re
· 2026
$110M – $115M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2025
Revenue
· 2025
$108M – $110M
Adjusted EBITDA
· Q2 2025
$0
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−66%
Bearish
Price vs 50-day avg
+69%
Bullish
RSI (14)
80
Bearish
MACD trend
Positive
Bullish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.07% of float · ▲ +11.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 9%
Range high $5
vs 200-day avg -66%
vs 50-day avg +69%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDXH
this stock
MDxHealth SA
|
$41.50M | -77.4% | — | — | 2.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDXH | +75.3% | +91.0% | -77.6% | +93.3% | -77.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +74.9% | +86.6% | -91.4% | +89.4% | -91.2% |